DC Tax Flash: IRS Posts Amount for Determining PCORTF Fee

Tax Alert

The Internal Revenue Service (IRS) today issued Notice 2020-44, which instructs on calculating the fee imposed by Internal Revenue Code section 4375 and section 4376 for policy years and plan years that end on or after October 1, 2019, and before October 1, 2020.

The guidance sets $2.54 as the adjusted applicable dollar amount that applies for determining the Patient-Centered Outcomes Research Trust Fund (PCORTF) fee. This amount is determined using the percentage increase in the projected per capita amount of the National Health Expenditures published by HHS in February 2019, the IRS explains. The notice also provides transition relief "for calculating the average number of covered lives as part of calculating the applicable fee for policy years and plan years that end on or after October 1, 2019, and before October 1, 2020," the IRS notes.

The five-page text of Notice 2020-44 is posted here.

Miller & Chevalier Coronavirus Task Force
The outbreak of COVID-19 is creating significant business and legal challenges for companies throughout the world. In response to client demand, the firm has formed an interdisciplinary task force to help businesses navigate these issues.

COVID-19 Resource Library
We also maintain a resource library of legislative responses and regulatory guidance related to COVID-19.

The information contained in this communication is not intended as legal advice or as an opinion on specific facts. This information is not intended to create, and receipt of it does not constitute, a lawyer-client relationship. For more information, please contact one of the senders or your existing Miller & Chevalier lawyer contact. The invitation to contact the firm and its lawyers is not to be construed as a solicitation for legal work. Any new lawyer-client relationship will be confirmed in writing.

This, and related communications, are protected by copyright laws and treaties. You may make a single copy for personal use. You may make copies for others, but not for commercial purposes. If you give a copy to anyone else, it must be in its original, unmodified form, and must include all attributions of authorship, copyright notices, and republication notices. Except as described above, it is unlawful to copy, republish, redistribute, and/or alter this presentation without prior written consent of the copyright holder.